KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma

AKIHIRO KITAGAWA1,2, TAKAAKI MASUDA1, JUNICHI TAKAHASHI1, TARO TOBO3, MIWA NODA1, YOSUKE KURODA1, QINGJIANG HU1, YUTA KOUYAMA1, YUTA KOBAYASHI1,2, SHOTARO KURAMITSU1, KUNIKA SATO1, ATSUSHI FUJII1, YUKIHIRO YOSHIKAWA1,2, HIROAKI WAKIYAMA1, DAII SHIMIZU1, YUSUKE TSURUDA1, HIDETOSHI EGUCHI2, YUICHIRO DOKI2, MASAKI MORT4 and KOSHI MIMORI1

Departments of 1Surgery and 3Clinical Laboratory Medicine, Kyushu University, Beppu Hospital, Oita, Japan; 2Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan; 4Department of Surgery and Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan

Abstract. Background/Aim: Kinesin family member 15 (KIF15) participates in the transport of macromolecules in essential cellular processes. In this study we evaluated the clinical relevance of KIF15 expression in hepatocellular carcinoma (HCC). Materials and Methods: Association between KIF15 expression and clinical outcomes in HCC patients was analyzed using three independent cohorts. Localization of KIF15 expression was assessed by immunohistochemical analysis. Co-culture experiments were performed using healthy donor peripheral blood mononuclear cells (PBMC) and HCC cell lines. Results: Immunohistochemical analysis showed that KIF15 was mainly expressed in inflammatory monocytes around cancer cells. Multivariate analysis indicated high KIF15 expression was an independent poor prognostic factor for survival. HCC cells with high expression of minichromosome maintenance protein 2 (MCM2) were located close to KIF15-expressing inflammatory monocytes. The proliferation ability of HCC cells was increased by co-culture with PBMC. Conclusion: High KIF15 expression in inflammatory monocytes in tumor tissues may serve as a prognostic marker for poor outcome in HCC.

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide (1, 2). HCC is essentially an incurable malignancy due to the limited availability of radical therapeutic approaches. In most cases, the only potentially curative treatment remains surgical resection and liver transplantation (3). It should be important to clarify the molecular mechanisms involved in HCC progression and identify novel prognostic molecular biomarkers of HCC to achieve improvements in survival.

Intracellular transport is fundamental for cellular function, survival and morphogenesis. After synthesis, cells transport and sort proteins and lipids to various destinations at appropriate velocities in organelles and protein complexes (4). Among the molecular motors that are involved intracellular transport, 3 large superfamilies have been identified, including kinesins, dyneins and myosins (5, 6). In the kinesin superfamily (KIF) of proteins, one of those motors for anterograde transport of mitochondria, comprise a group of proteins that share a highly conserved motor domain and facilitate the transport of mRNA, protein complexes and organelles in an ATP-and microtubule-dependent manner (4, 7, 8). Previous studies revealed that many KIFs are involved in carcinogenesis, invasion and metastasis of multiple human cancers, including HCC (9-12).

KIF15, which is the second tetrameric spindle motor (in addition to kinesin-5, Eg5), modulates spindle microtubule architecture with Tpx2 and drives centrosome separation during bipolar spindle assembly (13-15). KIF15 also plays an important role in tumor progression, as previously described (9, 16, 17). For instance, KIF15 is considered a key regulator that promotes G1/S phase transition via regulating the MEK-ERK signaling pathway. It represents a new therapeutic target for pancreatic cancer, although a detailed mechanism of KIF15 function is lacking (9). However, the clinical and biological significance of KIF15 expression in HCC has not been fully elucidated. In this study, we aimed to determine the clinical significance of KIF15 expression in HCC and investigated its biological role in HCC progression.
Materials and Methods

Public datasets. The Cancer Genome Atlas database (TCGA) via Broad Institute’s Firehose (http://gdac.broadinstitute.org/) and GSE14520 dataset via the GEO database (http://www.ncbi.nlm.nih.gov/) were analyzed in this study. There were mRNA expression data from 371 tumor tissues and 50 non-cancerous tissues in TCGA dataset and 247 tumor tissues and 239 non-cancerous tissues in the GSE14520 dataset. TCGA and GSE14520 sequencing data were normalized with quantile normalization (18).

Gene set enrichment analysis. The associations between KIF15 expression and previously defined gene sets were analyzed by gene set enrichment analysis (GSEA) using HCC expression profiles from the appropriate TCGA dataset. The biologically defined gene sets were obtained from the Molecular Signatures Database v5.2 (http://software.broadinstitute.org/gsea/msigdb/index.jsp).

Patients and sample collection from our patient cohort. Overall, 59 patients with HCC who underwent liver resection at the Kyushu University Beppu Hospital and its affiliated hospitals between 2000 and 2004 were enrolled in this study, as previously described (19-21). Tissues from resected tumors were immediately stored in RNAlater (Ambion, Austin, TX, USA), frozen in liquid nitrogen and kept at −80°C until RNA extraction. Corresponding non-cancerous liver tissues were also collected (available in 49 of 59 cases). A 5-year follow-up was conducted after surgery, and the average follow-up period for the 59 patients was 60.0 months (range=3.0-60.0 months).

Cell lines and cell culture. Established human hepatocellular carcinoma cell lines (HepG2 and HuH7), a monocyte cell line (THP1) and a fibroblast cell line (KMST-6) were purchased from the American Type Culture Collection. These cell lines were cultured in D-MEM (HepG2 and HuH7) or RPMI1640 (THP1 and KMST-6) (Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS) and 100 U/ml Pen/Strep, and PBMCs were enumerated in triplicate on 6-well plates and incubated at 37°C under 5% CO₂ with antibiotic selection.

RNA extraction. Total RNA was extracted from frozen tissue samples, cell lines and healthy donor peripheral blood mononuclear cells (PBMC) using ISOGEN (Nippon Gene, Tokyo, Japan), as previously described (22).

Reverse transcription-quantitative PCR (RT-qPCR). RT was performed using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA), as previously described (23, 24), and the quantitative polymerase chain reaction (qPCR) was performed using a LightCycler 480 SYBR Green I Master Mix (Roche, Basel, Switzerland) as previously described (23, 24). The following primers were used: KIF15: 5'-AATTTGCAGCCCATCTTGAGC-3' (sense) and 5'-CTGACCATTTGTCACGCTGC-3' (antisense); GAPDH: 5'-AGCCACATCGCTCAGACAC-3' (sense) and 5'-GCC CAATACGCAAAATTC-3' (antisense). The expression level of KIF15 mRNA was normalized to that of GAPDH.

Western blot analysis. Western blot analysis was performed as previously described (22, 25). The following antigen-specific antibodies were used: primary goat polyclonal antibody against MCM2 (sc-9839; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1:500; and, primary mouse polyclonal antibody against β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1:1,000. Expression of MCM2 proteins was normalized to the expression of β-actin.

Isolation of healthy donor PBMCs. PBMCs in 30 to 40 ml of blood were obtained from a healthy donor. The cells were collected in EDTA tubes and they were isolated using Ficoll-Paque PLUS (GE Healthcare, Japan) density gradient centrifugation.

PBMC culture and co-culture of HCC cell lines with PBMC. The isolated PBMCs were re-suspended in culture medium containing D-MEM (Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS) and 100 U/ml Pen/Strep, and PBMCs were enumerated in triplicate. Experiments that were performed with both HCC cell lines (HepG2 and HuH7) and PBMCs in order to find optimal co-culture conditions. Therefore, the control HCC cell lines were maintained in monocultures using the same medium. The viability of PBMCs after 7-14 days in culture always exceeded 30-50%.

We co-cultured HCC cell lines with PBMCs plated on 10-cm culture dishes (Thermo Fisher Scientific, USA). Cells were cocultured on culture inserts (FALCON, USA) for 7-10 days such that 6×10⁵ HepG2 were mixed with 1×10⁶ PBMC or 6×10⁵ HuH7 were mixed with 1×10⁵ PBMC. Total RNA from co-cultured HCC cell lines (HepG2 and HuH7) and PBMC were extracted using ISOGEN (Nippon Gene, Tokyo, Japan). For co-culture experiments, HepG2 and HuH7 cells were plated at a density of 3000 cells/well in triplicate on 6-well plates and incubated at 37°C under 5% CO₂ with antibiotic selection.

Colony formation assay. After 10 days, the colonies were stained using a Differential Quick Stain Kit (Sysmex) according to the manufacturer’s instructions. Visible colonies were photographed using a FUSION SOLO S. Colony counts were determined using the ImageJ software (version 1.80, NIH, Bethesda, MD, USA).

MTT assay. MTT assays were conducted using a Cell Proliferation Kit 1 (Roche Applied Science) to evaluate cell proliferation following the manufacturer’s instructions, as previously described (22).

Immunohistochemical analysis (IHC). Immunohistochemical analysis of KIF15 expression was performed with formalin-fixed paraffin-embedded surgical sections (FFPE) obtained from patients with HCC, or a HCC cell line (HepG2) or healthy donor PBMC, as previously described (21, 26). Primary rabbit polyclonal antibody against KIF15 (ab90735; Abcam) was used at a dilution of 1:200. Histological analysis was performed independently by an experienced research pathologist at the Kyushu University.

Immunofluorescence analysis (IF). Antibodies against KIF15 (anti-rabbit IgG 555, Cell Signaling) and MCM2 (anti-mouse IgG 488, Cell Signaling) were used to stain KIF15 protein and MCM2 protein, respectively in FFPE, at a dilution of 1:1,000 and 1:250, as described above and fluorescent images were observed using a fluorescence microscope (BZ-X700, Keyence, Osaka, Japan).

We counted the number of inflammatory monocytes and HCC cells stained clearly by antibody against KIF15 and MCM2 divided into several segments in a field of view at ×200 and examined the correlation between them.
Figure 1. Clinical significance of KIF15 expression in HCC tissues. (A) KIF15 mRNA expression in tumor tissues and non-cancerous tissues in our HCC patient cohort, TCGA dataset and GSE14520 dataset. (B) Immunohistochemical detection of KIF15 expression in a representative sample of HCC. Original magnifications: ×50, ×200 and ×400. (C) KIF15 mRNA expression in HCC cell lines (HepG2 and HuH7) and monocyte and fibroblast cell lines (THP1 and KMST-6, respectively). (D) Kaplan-Meier survival curve of 59 HCC patients from our patient cohort, 335 HCC patients from a TCGA dataset, and 242 HCC patients from the GSE14520 dataset based on KIF15 mRNA expression. (E) GSEA of HCC cases from a TCGA dataset.
Analyses were performed using the R version 3.1.1 (Vienna, Austria; http://www.R-project.org/).

### Table I. Univariate and multivariate analyses of clinicopathologic factors for overall survival in our HCC cases (N=59).

| Variable                                    | Univariate analysis | Multivariate analysis |
|---------------------------------------------|---------------------|-----------------------|
|                                            | HR                  | 95%CI                 | p-Value   | HR                  | 95%CI                 | p-Value   |
| Age≥65 (years)                              | 0.6                 | 0.24-1.60             | 0.294     |                     |                       |           |
| Gender (male/female)                        | 1.93                | 0.7-6.76              | 0.209     |                     |                       |           |
| Hepatitis B (present/absent)                | 1.3                 | 0.46-3.26             | 0.594     |                     |                       |           |
| Hepatitis C (present/absent)                | 1.21                | 0.49-3.23             | 0.673     |                     |                       |           |
| Child–Pugh classification (A/B and C)       | 1.13                | 0.26-3.37             | 0.845     |                     |                       |           |
|AFP median (ng/ml)                           | 4.18                | 1.59-13.03            | 0.003*    | 2.33                | 0.69-8.43             | 0.17      |
|Maximum tumor size ≥3 (cm)                  | 5.44                | 2.07-16.93            | <0.001*   | 3.57                | 1.14-13.57            | 0.02*     |
|Number of tumors (single/multiple)          | 1.49                | 0.55-3.64             | 0.405     |                     |                       |           |
|Portal vein invasion (present/absent)       | 1.55                | 0.58-4.12             | 0.537     |                     |                       |           |
|Hepatic vein invasion (present/absent)      | 1.48                | 0.55-3.99             | 0.495     |                     |                       |           |
|Biliary invasion (present/absent)           | 2.78                | 0.56-50.17            | 0.225     |                     |                       |           |
|Histological differentiationa (well, moderately/poorly) | 4.11                | 1.43-10.60            | 0.011*    | 0.87                | 0.27-2.88             | 0.82      |
|Expression (low/high)                        | 13.39               | 2.76-240.91           | <0.001*   | 8.83                | 1.66-163.31           | 0.006*    |

*WHO grades 1 and 2 or Edmondson-Steiner grade 1 and 2 were classified as well-differentiated or moderately differentiated. WHO grades 3 and 4 or Edmondson-Steiner grade 3 and 4 were classified as poorly differentiated. HR: Hazard ratio, CI: confidence interval, HBV: hepatitis B virus, HCV: hepatitis C virus, AFP: α-fetoprotein, HCC: hepatocellular carcinoma, WHO: World Health Organization. *Indicates statistical significance.

**Statistical analysis.** For clinical analysis, cases were divided into 2 groups using the minimum p-value approach based on the KIF15 expression level, which is a comprehensive method to identify the optimal risk separation cut-off point in continuous gene expression measurements for survival analysis in multiple datasets (27). For continuous variables, data were expressed as means±standard deviation, and statistical analysis was performed using Welch’s t-tests. The degree of linearity was estimated by Spearman’s rank correlation coefficient. Categorical variables were compared using chi square tests or Fisher’s exact tests. Overall survival (OS) was estimated using the Kaplan–Meier method, and the survival curves were compared using the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model to identify independent variables predictive of OS. p<0.05 was considered statistically significant. Data analysis of clinicopathological factors was performed using the JMP 13 software (SAS Institute, Cary, NC, USA), and other analyses were performed using the R version 3.1.1 (Vienna, Austria; http://www.R-project.org/).

**Results**

**KIF15 expression was up-regulated in human HCC tissues.** First, we analyzed KIF15 mRNA expression in HCC tissues and non-cancerous liver tissues using 2 public data sources (TCGA and GSE14520 datasets). Moreover, we measured KIF15 mRNA expression by RT-qPCR using 59 tumor tissues and 49 paired non-cancerous tissues from HCC patients in our hospital. We found that KIF15 mRNA expression in HCC tissues was significantly higher compared to non-cancerous tissues in our cohort and in two public databases (p<0.001, Figure 1A). Next, immunohistochemical analysis showed that KIF15 was mainly stained in the inflammatory monocytes infiltrating closely to cancer cells compared with non-cancerous tissues (Figure 1B). This is consistent with the fact that KIF15 mRNA expression level is lower in HCC cell lines (HepG2 and HuH7) compared to its expression in a monocyte cell line (THP1) and a fibroblast cell line (KMST-6) (Figure 1C). These results suggest that KIF15 is expressed mainly in tumor-associated monocytes in HCC.

**Prognostic significance of KIF15 expression in HCC tissues.** We performed prognostic analyses of KIF15 expression in 3 datasets (our patient cohort, a TCGA dataset, and the GSE15420 dataset). With each dataset, we divided the total cases into high- and low- KIF15 expression groups using the minimum p-value approach based on the KIF15 expression level, as described in the Materials and Methods section. Overall survival of the high KIF15 expression group was significantly poorer than that in the low-expression group in our patient cohort (log-rank test, n=59, p<0.01), TCGA dataset (log-rank test, n=335, p<0.001) and the GSE14520 dataset (log-rank test, n=242, p<0.001) (Figure 1D).

Then, we performed a multivariate analysis with all 4 variables affecting OS in univariate analyses in our patient cohort (KIF15 mRNA expression in HCC, AFP, maximum tumor size and histological differentiation). Of note, high KIF15 expression was an independent prognostic factor for poor outcome (p<0.01, HR=8.83, 95% CI=1.66-163.31) (Table I).

**Clinicopathological significance of KIF15 expression in HCC tissues.** The relationship between clinicopathological factors...
**Table II. KIF15 expression and clinicopathological factors in our HCC cases (N=59).**

| Factors                                | KIF15 mRNA expression | p-Value |
|----------------------------------------|-----------------------|---------|
|                                        | Low (n=20)            | High (n=39) |     |
| Age, years (mean±SD)                   | 67.9±6.6              | 64.9±10.0 | 0.239 0.131 |
| Gender                                 |                       |         |     |
| Male                                   | 17                    | 25      |     |
| Female                                 | 3                     | 14      |     |
| Etiology of HBV infection              |                       |         |     |
| Present                                | 5                     | 12      | 0.765 |
| Absent                                 | 15                    | 27      |     |
| Etiology of HCV infection              |                       |         |     |
| Present                                | 11                    | 24      | 0.780 |
| Absent                                 | 9                     | 15      |     |
| Child-Pugh classification              |                       |         | 1.000 |
| A                                      | 25                    | 27      |     |
| B and C                                | 4                     | 3       |     |
| AFP (μg/l)                              |                       |         |     |
| <median                                | 14                    | 15      | 0.051 |
| ≥median                                | 6                     | 23      |     |
| NA                                     | 1                     |         |     |
| Maximum tumor size (cm)                |                       |         |     |
| <3                                     | 17                    | 28      | 0.012* |
| ≥3                                     | 3                     | 11      |     |
| Number of tumors                       |                       |         |     |
| Single                                 | 15                    | 27      | 0.765 |
| Multiple                               | 5                     | 12      |     |
| Portal vein invasion                   |                       |         |     |
| Present                                | 3                     | 16      | 0.059 |
| Absent                                 | 13                    | 16      |     |
| NA                                     | 4                     | 7       |     |
| Hepatic vein invasion                  |                       |         | 1.000 |
| Present                                | 8                     | 16      |     |
| Absent                                 | 8                     | 16      |     |
| NA                                     | 4                     | 7       |     |
| Bile-duct invasion                     |                       |         |     |
| Present                                | 13                    | 29      | 0.366 |
| Absent                                 | 3                     | 3       |     |
| NA                                     | 4                     | 7       |     |
| Histological differentiation           |                       |         |     |
| Well or moderately                     | 18                    | 27      | 0.040* |
| Poorly                                 | 0                     | 8       |     |
| NA                                     | 2                     | 4       |     |

*WHO grades 1 and 2 or Edmondson-Steiner grade 1 and 2 were classified as well-differentiated or moderately differentiated. WHO grades 3 and 4 or Edmondson-Steiner grade 3 and 4 were classified as poorly differentiated. SD: Standard deviation, HBV: hepatitis B virus, HCV: hepatitis C virus, AFP: α-fetoprotein, NA: not available, HCC: hepatocellular carcinoma, WHO: World Health Organization. *Indicates statistical significance.

**KIF15 expression was positively associated with the MYC/E2F target pathway in HCC tissues.** To investigate the effect of KIF15 expression on inflammatory monocytes in HCC tissues, we performed GSEA using TCGA dataset. GSEA showed a significant positive correlation between KIF15 expression and the MYC/E2F target gene set in HCC tissues (Figure 1E).

**HCC cells with a high expression of MCM2 were located close to inflammatory monocytes expressing KIF15.** MCM2 expression has been found superior to Ki-67 as a marker defining the proliferative status of tumor cells and is associated with prognosis in many cancers (28, 29). Immunofluorescent staining showed that MCM2 was mainly stained on HCC cells around inflammatory monocytes that expressed KIF15 (Figure 2A). The number of inflammatory monocytes that expressed KIF15 was positively correlated with the number of HCC cells that expressed MCM2 (Pearson correlation coefficient R=0.818, p<0.05) (Figure 2B). Proliferating cell nuclear antigen (PCNA) is a nuclear protein that is necessary for DNA synthesis and it appears in the nucleus primarily during the S phase of the cell cycle (30). We observed that KIF15 mRNA expression was positively correlated with MCM2 and PCNA in the selected TCGA dataset (Figure 2C). These data suggest that inflammatory monocytes that expressed KIF15 promoted HCC cell proliferation.

**KIF15-expressing PBMC promoted HCC cell proliferation in vitro.** Based on our clinical findings described above, we hypothesized that inflammatory monocytes that expressed KIF15 promoted progression of HCC. To examine the biological significance of KIF15-expressing inflammatory monocytes close to cancer cells, we performed in vitro proliferation assays using HepG2 and HuH7 cells co-cultured with healthy donor PBMCs in which KIF15 was expressed (Figure 3A). In colony proliferation assays (Figure 3B) and MTT assays (Figure 3C), HepG2 and HuH7 cells co-cultured with PBMC showed a high proliferation ability compared to the controls. Furthermore, western blot analysis showed that the expression of MCM2 protein was upregulated in HepG2 cells co-cultured with PBMC (Figure 3D).

**Discussion**

There is increasing evidence that tumor-associated inflammatory monocytes are activated by tumor cells and can facilitate tumor growth or metastasis by causing immunosuppression, angiogenesis or the epithelial–mesenchymal transition (EMT) of tumor cells in various malignancies, including HCC (31-34). For instance, TNF and IL-1β derived from tumor-activated monocytes synergistically induce cancer cell autophagy and EMT of cancer cells and promote tumor
metastasis by activating the NF-κB-SNAI1 signaling pathway in the HCC microenvironment (31).

In this study, we showed that KIF15 was expressed in inflammatory monocytes around HCC cells, and its high expression predicted a poor prognosis of HCC patients. Clinicopathological analysis indicated that high expression of KIF15 in tumor tissues was positively associated with clinicopathological factors associated with tumor aggressiveness, such as tumor size and tumor differentiation in HCC. Furthermore, KIF15 mRNA expression was significantly correlated with the MYC/E2F target gene set by GSEA. These results suggest that KIF15 serves as a novel prognostic biomarker in HCC patients, as well as an expression marker of tumor-associated monocytes in HCC.

Based on the clinical findings described above, we hypothesized that inflammatory monocytes that express KIF15 may promote cancer cell progression of HCC. First, in immunofluorescence staining, we observed that HCC cells with high MCM2 expression were located close to KIF15-expressing inflammatory monocytes. Moreover, a positive correlation between KIF15 mRNA expression and markers of cell proliferation (MCM2 and PCNA) was observed in TCGA dataset. Next, we performed *in vitro* proliferation assays of HCC cells co-cultured with KIF15-expressing PBMC. As expected, proliferation ability was increased by co-culture with PBMC. These findings suggest that KIF15-expressing inflammatory monocytes could promote the proliferation of HCC cells.

There are limitations in this study. We provided clinical and biological evidence that KIF15-expressing inflammatory monocytes could promote cancer cell proliferation in HCC. Given that GSEA showed positive correlation between KIF15 mRNA expression and MYC/E2F TARGETS gene set in HCC tissues, implying that KIF15-expressing inflammatory monocytes might promote the progression of HCC via the MYC/E2F pathway. However, the mechanism remains unknown. Further study will be required to elucidate the biological role of KIF15 expression in inflammatory monocytes in HCC.

In conclusion, we demonstrated that KIF15 is expressed mainly in inflammatory monocytes around HCC cells,
namely, tumor-associated monocytes. Its high expression could be a novel prognostic biomarker of poor survival of HCC patients possibly in part through promoting the proliferation of HCC cells. KIF15 might be a useful molecular therapeutic target in HCC microenvironment as its inhibition in tumor-associated monocytes could reduce cancer cell proliferation.

Conflicts of Interest

The Authors have no conflicts of interest.

Authors’ Contributions

AK wrote the manuscript. AK conducted the process of experiments. AK, TM, JT, TT, MN, YK, QH, YK, SK, KS, AF, YY, HW, DS, YT, HE, YD, MM and KM designed the study and data interpretation. AK and JT prepared the organization of figures and statistical analysis.

Acknowledgements

The Authors would like to thank K. Oda, M. Kasagi, S. Sakuma, N. Mishima, T. Kawano, M. Oshiumi and M. Utou for their technical assistance. This work was supported in part by the following Grants and foundations: Japan Society for the Promotion of Science Grant-in-Aid for Science Research (Grant Numbers JP16K07177, JP16K10543, JP17K16454, JP17K16521, JP17K10593 and JP17K19608); OITA Cancer Research Foundation; Daiwa Securities Health Foundation; Grant-in-Aid for Scientific Research on Innovative Areas (15H0912); Priority Issue on Post-K computer (hp170227) (hp170227, hp160219); JSPS KAKENHI (15H05707); Japanese Foundation for Multidisciplinary Treatment of Cancer. HCC clinical samples were provided by the Oita Red Cross Hospital, Hiroshima Red Cross Hospital, Atomic-bomb Survivors Hospital, and lizuwa Hospital.
Saeki H, Oki E, Maehara Y, Suzuki A and Mimori K: Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes- associated protein 1 expression in gastric cancer. Oncotarget 8(64): 107666-107677, 2017. PMID: 29296196. DOI: 10.18632/oncotarget.22587

Mizuno H, Kitada K, Nakai K and Sarai A: PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMJ Med Genomics 2: 18, 2009. PMID: 19393097. DOI: 10.1186/1755-8794-2-18

Huang H, Huang W, Lin C, Eng HL, Li SH, Li CF, Lu D, Yu SC and Hsiung CY: Immunohistochemical expression of p16INK4a, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: Prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol 13(12): 1633-1644, 2006. PMID: 17013685. DOI: 10.1245/s10434-006-9188-4

Yousef EM, Furrer D, Laperriere DL, Tahir MR, Mader S, Diorio C and Gaboury LA: MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Mod Pathol 30(5): 682-697, 2017. PMID: 28084344. DOI: 10.1038/modpathol.2016.231

Mathews MB, Bernstein RM, Franz BR Jr and Garrels JI: Identity of the proliferating cell nuclear antigen and cyclin: Nature 241(306): 374-376, 1984. PMID: 6145097. DOI: 10.1038/241374a0

Chen DP, Ning WR, Li XF, Wei Y, Lao XM, Wang JC, Wu Y and Zheng L: Peritumoral monocytes induce cancer cell autophagy to facilitate the progression of human hepatocellular carcinoma. Autophagy 14(8): 1335-1346, 2018. PMID: 29940792. DOI: 10.1080/15548627.2018.1474994

Kitagawa et al: KIF15 in Hepatocellular Carcinoma

Received November 12, 2019
Revised December 1, 2019
Accepted December 4, 2019

149